334 related articles for article (PubMed ID: 16224539)
1. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S
J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling.
Khalfaoui-Bendriss G; Dussault N; Fernandez-Sauze S; Berenguer-Daizé C; Sigaud R; Delfino C; Cayol M; Metellus P; Chinot O; Mabrouk K; Martin PM; Ouafik L
Oncotarget; 2015 Apr; 6(10):7536-53. PubMed ID: 25924235
[TBL] [Abstract][Full Text] [Related]
3. Vascular disrupting effect of combretastatin A-4 phosphate with inhibition of vascular endothelial cadherin in canine osteosarcoma-xenografted mice.
Izumi Y; Takagi S
Res Vet Sci; 2019 Feb; 122():1-6. PubMed ID: 30439557
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
5. Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells.
Izumi Y; Aoshima K; Hoshino Y; Takagi S
Res Vet Sci; 2017 Jun; 112():222-228. PubMed ID: 28527400
[TBL] [Abstract][Full Text] [Related]
6. Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells.
Ding X; Zhang Z; Li S; Wang A
Oncol Res; 2011; 19(7):303-9. PubMed ID: 21936400
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin.
Menon C; Ghartey A; Canter R; Feldman M; Fraker DL
Ann Surg; 2006 Nov; 244(5):781-91. PubMed ID: 17060772
[TBL] [Abstract][Full Text] [Related]
8. The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate.
Holmes T; Brown AW; Suggitt M; Shaw LA; Simpson L; Harrity JPA; Tozer GM; Kanthou C
Sci Rep; 2020 Jun; 10(1):9926. PubMed ID: 32555222
[TBL] [Abstract][Full Text] [Related]
9. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.
Petit I; Karajannis MA; Vincent L; Young L; Butler J; Hooper AT; Shido K; Steller H; Chaplin DJ; Feldman E; Rafii S
Blood; 2008 Feb; 111(4):1951-61. PubMed ID: 18024794
[TBL] [Abstract][Full Text] [Related]
10. Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent.
Yuan W; Su C; Yang X; Li Y; Cao Y; Liang X; Liu J
J Cell Biochem; 2019 Oct; 120(10):16978-16989. PubMed ID: 31111562
[TBL] [Abstract][Full Text] [Related]
11. The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their association.
Ali N; Yoshizumi M; Yano S; Sone S; Ohnishi H; Ishizawa K; Kanematsu Y; Tsuchiya K; Tamaki T
J Pharmacol Sci; 2006 Sep; 102(1):112-20. PubMed ID: 16974068
[TBL] [Abstract][Full Text] [Related]
12. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
13. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
15. Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-cadherin Internalization.
Lei X; Chen M; Huang M; Li X; Shi C; Zhang D; Luo L; Zhang Y; Ma N; Chen H; Liang H; Ye W; Zhang D
Theranostics; 2018; 8(2):384-398. PubMed ID: 29290815
[TBL] [Abstract][Full Text] [Related]
16. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule.
Tang FY; Nguyen N; Meydani M
Int J Cancer; 2003 Oct; 106(6):871-8. PubMed ID: 12918064
[TBL] [Abstract][Full Text] [Related]
17. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
18. Transcatheter Arterial Embolization Combined with Anti-vascular Agent Combretastatin A4 Phosphate Inhibits Growth and Vascularization of Liver Tumor in an Animal Model.
Zhao H; Wu ZZ; Ren Q; Wu JJ; Wang Y; Feng JW; Rao M; Deng Q; Hu HY
Curr Med Sci; 2022 Dec; 42(6):1240-1247. PubMed ID: 36462132
[TBL] [Abstract][Full Text] [Related]
19. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.
Griggs J; Skepper JN; Smith GA; Brindle KM; Metcalfe JC; Hesketh R
Am J Pathol; 2002 Mar; 160(3):1097-103. PubMed ID: 11891206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
